The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc Announces Submission of Responses to EMA Day 120 Questions
Stockholm, January 12, 2021 – Intervacc AB (publ) announces that the responses to the Day 120 questions regarding the Company’s Marketing Authorization Application (MAA) for Strangvac® has been submitted today to the European Medicines Agency (EMA). Intervacc is...Intervacc appoints Emma Hartman as Global Product Manager for Strangvac
Stockholm, November 25, 2020 – The animal health group Intervacc AB (publ) has appointed Emma Hartman in the role of global product manager for Strangvac, a vaccine that is expected to become a game-changer in the fight against the global equine disease...Quality Assurance (QA) Manager at Intervacc
We have an exciting new opportunity for a Quality Assurance (QA) Manager who will be responsible for quality management of external manufacturing and supply of Intervacc’s products. The Quality Manager will have a central role in oversight and management of external...Interim report January – September 2020
The period in summary Third quarter July 1 – September 30, 2020 Our marketing authorization application for Strangvac was submitted to the European Medicines Agency, EMA, at the end of February. During the third quarter, we have strengthened the dossier in the areas...Nyhetstjänster
